SLC5A2 and diabetic kidney disease: Clinically validated therapies targeting SGLT2, ENaC, and TRP channels (e.g., dapagliflozin, finerenone, GSK2193874) have marked a paradigm shift in DKD management from “symptom control” to “mechanism-based intervention” (82–92, 99–102).